Merck KGaA Expands and Extends their License of MetaCore from GeneGo
Merck KGaA values the completeness of content coverage in MetaCore from signaling ligands to core metabolic changes, its intuitive interface and the system's applicability in many therapeutic areas and biomarkers.
"We see MetaCore as a further step into systems biology, a novel discipline which holds much promise for pharmaceutical research," said Dr. Friedrich Rippmann, Director of Bio- and Chemoinformatics.
"We are very pleased to expand our relationship with Merck KGaA. Our experience with them as a customer is very positive, with excellent, constructive feedback and open exchange of development ideas," said Julie Bryant, Vice President of Business Development at GeneGo.
"Now, more groups at Merck KGaA will be able to use MetaCore in both early discovery and new compound safety testing."